BIOLASE INC (BIOL) Forecast, Price Target & Analyst Ratings
NASDAQ:BIOL • US0909117022
0.129 USD
-0.02 (-13.19%)
At close: Jun 18, 2024
0.109 USD
-0.02 (-15.5%)
After Hours: 6/18/2024, 8:15:46 PM
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for BIOLASE INC (BIOL).
Forecast Snapshot
Consensus Price Target
$1.99
+ 1,441.86% Upside
Next Earnings Forecast
Release DateAug 8, 2024
PeriodQ3 / 2024
EPS Estimate-$0.07
Revenue Estimate11.81M
ChartMill Buy Consensus
80.00%
Weighted Analyst Rating Score
Price Target Details & History
Consensus Price Target and Range
Mean target
$1.99
Upside
+ 1,441.86%
From current price of $0.13 to mean target of $1.99, Based on 9 analyst forecasts
Low
$0.40
Median
$1.99
High
$3.68
Price Target Revisions
1 Month
-82.63%
3 Months
-86.55%
Price Target Summary
9 Wall Street analysts provided a forecast for the next 12 months for BIOL. The average price target is 1.99 USD. This implies a price increase of 1441.86% is expected in the next year compared to the current price of 0.129.
The average price target has been revised downward by 86.55% in the past 3 months.
Analyst Ratings & History
Current Analyst Ratings
Analyst Ratings History
Analyst Ratings Consensus
ChartMill Buy Consensus
80.00%
BIOL was analyzed by 9 analysts. The buy percentage consensus is at 80. So analysts seem to be have mildly positive about BIOL.
In the previous month the buy percentage consensus was at a similar level.
BIOL was analyzed by 9 analysts. More opinions would make the average more meaningful.
Recent Upgrades & Downgrades
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2024-10-02 | Benchmark | Reiterate | Speculative Buy -> Speculative Buy |
| 2024-09-03 | Ascendiant Capital | Maintains | Buy -> Buy |
| 2024-08-12 | Benchmark | Reiterate | Speculative Buy -> Speculative Buy |
| 2024-05-14 | Benchmark | Reiterate | Speculative Buy -> Speculative Buy |
| 2024-04-01 | Ascendiant Capital | Maintains | Buy -> Buy |
| 2024-03-22 | Benchmark | Maintains | Speculative Buy -> Speculative Buy |
| 2023-05-31 | Lake Street | Maintains | Buy -> Buy |
| 2023-03-29 | Benchmark | Reiterate | Speculative Buy |
| 2023-03-29 | Maxim Group | Maintains | Buy |
| 2022-05-20 | Lake Street | Initiate | Buy |
Next Earnings Forecast Details
Next Earnings Details
Release DateAug 8, 2024
PeriodQ3 / 2024
EPS Estimate-$0.07
Revenue Estimate11.81M
Revenue Q2Q8.14%
EPS Q2Q98.30%
Number of Analysts5
Next Earnings Revisions
Revenue (1 Month)
-4.26%
Revenue (3 Months)
-8.58%
EPS (1 Month)
-50.00%
EPS (3 Months)
84.04%
Next Earnings Summary
BIOL is expected to report earnings on 8/8/2024. The consensus EPS estimate for the next earnings is -0.07 USD and the consensus revenue estimate is 11.81M USD.
The next earnings revenue estimate has been revised downward by 8.58% in the past 3 months. Downward revisions are a negative sign and indicate that analysts are more pessimistic about the next earnings compared to 3 months ago.
Full Analyst Estimates
Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates
| 2021 | 2022 | 2023 | 2024 | 2025 | ||
|---|---|---|---|---|---|---|
| Revenue YoY % growth | 39.19M 72.04% | 48.46M 23.65% | 49.164M 1.45% | 51.687M 5.13% | 55.72M 7.80% | |
| EBITDA YoY % growth | -15.72M 12.86% | -24.84M -58.02% | -15.139M 39.05% | -4.794M 68.33% | -306K 93.62% | |
| EBIT YoY % growth | -16.12M 13.05% | -25.34M -57.20% | -17.937M 29.21% | -7.863M 56.16% | -5.035M 35.96% | |
| Operating Margin | -41.13% | -52.29% | -36.48% | -15.21% | -9.04% | |
| EPS YoY % growth | -3.25 62.86% | -410.00 -12,515.38% | -31.89 92.22% | -0.45 98.59% | -0.10 78.41% |
All data in USD
Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates
| Q3 / 24 | Q4 / 24 | Q1 / 25 | Q2 / 25 | Q3 / 25 | Q4 / 25 | |
|---|---|---|---|---|---|---|
| EPS Q2Q % growth | -0.07 98.30% | -0.03 98.26% | -0.06 83.00% | -0.01 87.25% | -0.02 69.23% | -0.03 |
| Revenue Q2Q % growth | 11.81M 8.14% | 15.637M 15.92% | 10.71M 5.72% | 15.606M 35.00% | 12.954M 9.69% | 16.473M 5.35% |
| EBITDA Q2Q % growth | -918K 41.53% | 1.071M 147.01% | -2.652M 31.40% | -816K -23.08% | -1.224M -33.33% | 1.734M 61.90% |
| EBIT Q2Q % growth | -1.839M 50.30% | 372.637K 107.34% | -2.601M 42.53% | -816K 50.41% | -1.173M 36.21% | 153K -58.94% |
All data in USD
Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data
Long Term Forward Growth Forecast Summary
Long Term EPS Growth (CAGR)
EPS Next 3 Year
N/A
EPS Next 5 Year
N/A
Long Term Revenue Growth (CAGR)
Revenue Next 3 Year
N/A
Revenue Next 5 Year
N/A
Long Term EBIT Growth (CAGR)
EBIT Next 3 Year
N/A
EBIT Next 5 Year
N/A
BIOLASE INC / BIOL Forecast FAQ
Can you provide the average price target for BIOLASE INC stock?
9 analysts have analysed BIOL and the average price target is 1.99 USD. This implies a price increase of 1441.86% is expected in the next year compared to the current price of 0.129.
When does BIOLASE INC (BIOL) report earnings?
BIOLASE INC (BIOL) will report earnings on 2024-08-08, after the market close.
What are the consensus estimates for BIOL stock next earnings?
The consensus EPS estimate for the next earnings of BIOLASE INC (BIOL) is -0.07 USD and the consensus revenue estimate is 11.81M USD.
What is the number of analysts for BIOL stock?
The number of analysts covering BIOLASE INC (BIOL) is 9.